跳至主要内容
临床试验/TCTR20240519007
TCTR20240519007尚未招募2 期

Clinical study of diabetes-specific formulas in patients with diabetes mellitus or prediabetes

Agricultural Research Development Agency (Public Organization)0 个研究点目标入组 105 人开始时间: 2024年5月19日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
105

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 60 Years(—)
性别
All

入选标准

  • 1.Aged between 18-60 years.
  • 2.Stable weight or weight change not exceeding 5% for at least 3 months prior to joining the research, with a body weight between 70-200 kilograms.
  • 3.Waist circumference exceeding standard limits: > 90 cm (36 inches) for men and > 80 cm (32 inches) for women, but not exceeding 120 cm.
  • 4.Diagnosed as at risk for diabetes, defined as having a fasting plasma glucose of 100-125 mg/dL or HbA1c of 5.7-6.5%, or diagnosed with diabetes and treated with lifestyle modifications alone or in combination with metformin, with HbA1c =< 8%.
  • 5.Health check-up results within the past year (if not available, the participant cannot join the study).
  • 6.If taking medications such as antihypertensives, metformin, or lipid-lowering drugs, there should be no changes in medication for 3 months prior to the study, and participants must not be using insulin or other diabetes medications apart from metformin.
  • 7.Willing to participate in the research by signing the consent form and strictly following the research procedures and dietary guidelines.

排除标准

  • 1.History of severe hypoglycemia with neuroglycopenia within the past 3 months.
  • 2.History of severe diabetic complications such as amputation or diabetic coma.
  • 3.History of impaired gastrointestinal function, such as short bowel syndrome.
  • 4.Impairment in cardiac, pulmonary, or circulatory function, such as ischemic heart disease or stroke, or history of heart failure within 6 weeks prior to joining the research.
  • 5.Significant abnormal laboratory results: hemoglobin < 10 g/dL, WBC < 3,000 ml (x103/uL), platelet count < 100,000 ml (x103/uL), liver enzymes (ALT, AST) > 3 times the upper limit of normal, and total bilirubin > 2 times the upper limit of normal.
  • 6.Abnormal kidney function: GFR < 60 mL/min/1.73 m2 (MDRD).
  • 7.Mental impairment, alcohol addiction, or substance abuse.
  • 8.Symptomatic thyroid dysfunction such as hypothyroidism or hyperthyroidism.
  • 9.History of cancer or presence of cancer cells within the past 5 years.
  • 10.Pregnant or breastfeeding women or those refusing contraception.
  • 11.Use of herbal medicines, supplements, or steroids (except topical steroids) for at least 7 consecutive days, or participation in other research projects within 4 weeks prior to this study.
  • 12.Allergy to components or ingredients of the medical foods being tested.
  • 13.History of lactose intolerance.
  • 14.Contraindications or potential hazards from BIA (Bioelectrical Impedance Analysis), including:
  • 14.1. Individuals with electrical devices or metal implants that affect body conductivity, such as pacemakers, metallic heart valves, cochlear implants, vascular clips/coils, or prostheses.
  • 14.2. Individuals unable to grasp the handles for arm BIA.
  • 14.3. Individuals unable to stand upright or requiring support for balance.

研究者

相似试验

Clinical study of diabetes-specific formulas in... | 临床试验